Article
Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer.
PloS one - 1 Jan 2018
Traylor Matthew, Walker Jemma L, Corrigan Adele A, Hernandez Monica A, Newhouse Stephen J, Folarin Amos A, Patel Hamel, Ross Paul J, Sanderson Jeremy D, Spicer James, Prescott Natalie J, Mathew Christopher G, Marinaki Anthony M, Lewis Cathryn M
Abstract excerpt
Fluoropyrimidines, including 5-fluororacil (5FU) and its pro-drug Capecitabine, are the common treatment for colorectal, breast, neck and head cancers-either as monotherapy or in combination therapy. Adverse reactions (ADRs) to the treatment are common and often result in treatment discontinuation or dose reduction. Factors contributing to ADRs, including genetic variation, are poorly characterized. We performed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
